TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases

GlobeNewswire Inc. Logo GlobeNewswire Inc. • •By Monte Rosa Therapeutics
Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases

Monte Rosa Therapeutics presented preclinical data on MRT-8102, a molecular glue degrader targeting NEK7, which shows potential in treating cardiovascular and cardiometabolic diseases by modulating the NLRP3 inflammasome pathway.

Insights
TGT   neutral

Mentioned as a platform for wishlist donations, with no significant positive or negative context


GLUE   positive

Company presented promising preclinical data demonstrating potential breakthrough in treating inflammatory diseases, with initial Phase 1 study on track and unique approach to targeting cardiovascular inflammation